Brind.

FDA granted Breakthrough Therapy designation to denifanstat, a drug developed by Sagimet Biosciences for MASH treatment.

2 reports, 1 independent Updated Aug 26

Gone quiet

Reports: 2
Developments: 1
Repetition: 50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

FDA granted Breakthrough Therapy designation to denifanstat, a drug developed by Sagimet Biosciences for MASH treatment.

Who's involved

What this event is mainly about

FDA mash

Keep exploring

The entities involved

FDA
- The illegal U.S. vape market is estimated to be worth $9 billion, fueled by unauthorized imports from China, while products must meet FDA authorization standards.Sun 20:36
- VDPHL01 and Veradermics, Incorporated are seeking FDA approval for their lead therapies targeting hair loss.Sun 20:31
mash
fast genome and metagenome distance estimation using MinHash

Nothing else this week.

Coverage

Newest first; wire copies grouped

Aug 26GlobeNewswireSagimet Biosciences to Participate in Two Upcoming Investor Conferences SAN MATEO, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutica
Aug 5GlobeNewswireSagimet Biosciences to Participate in the Canaccord Genuity 45th Annual Growth Conference SAN MATEO, Calif., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stag